Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECI 830

Next Previous
Drug Profile

ECI 830

Alternative Names: CDK2-IN-37; ECI-830; NVP-ECI-830

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Alcohols; Amines; Antineoplastics; Cyclohexanes; Cyclopropanes; Ethers; Ketones; Pyrazoles; Pyrimidines; Pyrroles; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 28 Jul 2026 Chemical structure information added
  • 22 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from the preclinical studies in HER2 negative breast cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 22 Apr 2026 Pharmacodynamics data from the preclinical studies in Breast cancer and Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top